Updated Exploratory Analysis From Trial With NSCLC Patients
Several publications have shown that the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immunotherapies are correlated with improvements in disease-free survival in the adjuvant setting in patients with non-small lung cancer (NSCLC). A recent study indicated that using the third-generation EGFR-TKI, osimertinib, yielded an enhanced survival rate and diminished recurrence risk among patients with NSCLC. Read more.

Artificial Intelligence Tool Predicts Risk of Lung Cancer
Low-dose computed tomography for lung cancer screening has been proven to be effective; however, less than 10% of eligible patients are screened annually per recommendations from the U.S. Preventative Service Task Force. In a recent publication, researchers developed and examined an artificial intelligence tool to predict the risk of cancer and discussed the training and validation of this novel tool. Read more.

Impact of NSAIDs on Immunotherapy Efficacy in NSCLC
Research demonstrates that immunotherapy such as immune checkpoint inhibitors improves overall survival in patients with metastatic and locally advanced non-small cell lung cancer (NSCLC); however, the clinical response rates have been suboptimal, and strategies are warranted to improve clinical outcomes. Learn more about a recent study involving nonsteroidal anti-inflammatory drug (NSAID) use and overall survival with immune checkpoint inhibitor administration.